Catalog No.
DHD41001
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
CD11A, Leukocyte function-associated molecule 1 alpha chain, Leukocyte adhesion glycoprotein LFA-1 alpha chain, LFA-1A, CD11 antigen-like family member A, CD11a, ITGAL, Integrin alpha-L
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P20701
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
hu1124, CAS: 214745-43-4
Clone ID
Efalizumab
Drug-induced Guillain-Barré Syndrome: a disproportionality analysis based on the US FDA adverse event reporting system., PMID:40220275
PBPK-based translation from preclinical species to humans for the full-size IgG therapeutic efalizumab., PMID:39411068
Effect of Biologic Therapies on Airway Hyperresponsiveness and Allergic Response: A Systematic Literature Review., PMID:37496824
A Multi-Modal Approach to Islet and Pancreas Transplantation With Calcineurin-Sparing Immunosuppression Maintains Long-Term Insulin Independence in Patients With Type I Diabetes., PMID:37359825
Review of natural compounds for potential psoriasis treatment., PMID:36995575
Allosteric targeting resolves limitations of earlier LFA-1 directed modalities., PMID:36921634
Different Treatment Modalities of Oral Lichen Planus-A Narrative Review., PMID:36661563
Toward systems-informed models for biologics disposition: covariates of the abundance of the neonatal Fc Receptor (FcRn) in human tissues and implications for pharmacokinetic modelling., PMID:36626943
Progressive multifocal leukoencephalopathy in anti-CD20 and other monoclonal antibody (mAb) therapies used in multiple sclerosis: A review., PMID:36283150
Bullous pemphigoid induced by biologic drugs in psoriasis: a systematic review., PMID:35694729
Construction of miRNA-regulated drug-pathway network to screen drug repurposing candidates for multiple sclerosis., PMID:35356949
Biologic Therapy for Moderate to Severe Psoriasis. Real-World Follow-up of Patients Who Initiated Biologic Therapy at Least 10 Years Ago., PMID:35226302
Identification of Molecular Signatures and Candidate Drugs in Vascular Dementia by Bioinformatics Analyses., PMID:35221911
Guselkumab-associated bullous pemphigoid in a psoriasis patient: A case report and review of the literature., PMID:34791777
Risk of herpes zoster associated with biological therapies for psoriasis and psoriatic arthritis: A systematic review and meta-analysis., PMID:34622837
Risk of Herpes Zoster Among Psoriasis Patients Taking Biologics: A Network Meta-Analysis of Cohort Studies., PMID:34150802
Therapeutic management in paediatric alopecia areata: A systematic review., PMID:33630354
Direct T-cell Inhibition and Agents Targeting T-cell Migration and Chemotaxis., PMID:32334982
Evolution of the inclusion/exclusion criteria and primary endpoints in pivotal trials of biologics and small oral molecules for the treatment of psoriasis., PMID:32167790
Anti-αLβ2 antibodies reveal novel endocytotic cross-modulatory functionality., PMID:31985813
Targeting the cutaneous lymphocyte antigen (CLA) in inflammatory and neoplastic skin conditions., PMID:31951753
Adverse Events in Patients With Rheumatoid Arthritis and Psoriatic Arthritis Receiving Long-Term Biological Agents in a Real-Life Setting., PMID:31572173
Partial and Transient Clinical Response to Omalizumab in IL-21-Induced Low STAT3-Phosphorylation on Hyper-IgE Syndrome., PMID:31355024
Interfering with leukocyte trafficking in Crohn's disease., PMID:31327399
Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances., PMID:31127023
Systemic treatments for alopecia areata: A systematic review., PMID:30191561
A review of neurologic complications of biologic therapy in plaque psoriasis., PMID:29529105
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors)., PMID:29427804
Biologic Agents In Systemic Dermatotherapy: Cutaneous And Systemic Side Effects., PMID:28521707
Incidence and Prevalence of Psoriasis in Denmark., PMID:28417141
Anti‑cytokine therapy for psoriasis - not only TNF‑α blockers. Overview of reports on the effectiveness of therapy with IL‑12/IL‑23 and T and B lymphocyte inhibitors., PMID:28026823
Biological therapies (immunomodulatory drugs), worsening of psoriasis and rebound effect: new evidence of similitude., PMID:27914574
A mathematical analysis of rebound in a target-mediated drug disposition model: II. With feedback., PMID:27832321
Targeted Delivery of an Anti-inflammatory PDE4 Inhibitor to Immune Cells via an Antibody-drug Conjugate., PMID:27731313
Downstream effect profiles discern different mechanisms of integrin αLβ2 inhibition., PMID:27613223
Pragmatic Multicriteria Decision Analysis (MCDA) Combined With Advanced Pharmacoepidemiology for Benefit-Risk Assessments of Medicines Adapted to the Real-Life Constraints of Regulators: Development and Case Study., PMID:30231761
JC Polyomavirus Abundance and Distribution in Progressive Multifocal Leukoencephalopathy (PML) Brain Tissue Implicates Myelin Sheath in Intracerebral Dissemination of Infection., PMID:27191595
Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies., PMID:26892034
Neonatal Immune Tolerance Induction to Allow Long-Term Studies With an Immunogenic Therapeutic Monoclonal Antibody in Mice., PMID:26603888
Comorbidity as a predictor for drug survival of biologic therapy in patients with psoriasis., PMID:26470689
Prevalence of latent tuberculosis infection in patients with moderate to severe psoriasis taking biologic therapies in a dermatologic private practice in Miami, Florida., PMID:26108266
Unusual case of B cell lymphoma after immunosuppressive treatment for psoriasis., PMID:25914782
Immunology of progressive multifocal leukoencephalopathy., PMID:25740538
Adalimumab in the treatment of moderate-to-severe chronic plaque psoriasis in patients switching from other biologics., PMID:25665143
Adverse drug reactions in dermatology., PMID:25622648
Prediction of the Pharmacokinetics, Pharmacodynamics, and Efficacy of a Monoclonal Antibody, Using a Physiologically Based Pharmacokinetic FcRn Model., PMID:25601866
Immunomodulatory treatments in epilepsy., PMID:25510946
Leukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory disease., PMID:25448040
A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy., PMID:25404234
For research use only. Not for human or drug use.
